becampanel becampanel becampanel (inn) (code name amp397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the ampa receptor (ic50 = 11 nm). it was investigated as an anticonvulsant for the treatment of epilepsy by novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials. becampanelclinical dataatc codenoneidentifiers iupac name (methyl)phosphonic acid cas number188696-80-2pubchem cid5491960chemspider4590791uniix3d0o800ajcomptox dashboard (epa)dtxsid50172241 chemical and physical dataformulac10h11n4o7pmolar mass330.193 g·mol−13d model (jsmol)interactive image smiles c1c(cc2c(c1cncp(=o)(o)o)c(=o)c(=o)2)(=o) inchi inchi=1s/c10h11n4o7p/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11h,3-4h2,(h,12,15)(h,13,16)(h2,19,20,21)key:abfmmczfkuijgq-uhfffaoysa-n